HRP20161612T2 - Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih - Google Patents

Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih Download PDF

Info

Publication number
HRP20161612T2
HRP20161612T2 HRP20161612TT HRP20161612T HRP20161612T2 HR P20161612 T2 HRP20161612 T2 HR P20161612T2 HR P20161612T T HRP20161612T T HR P20161612TT HR P20161612 T HRP20161612 T HR P20161612T HR P20161612 T2 HRP20161612 T2 HR P20161612T2
Authority
HR
Croatia
Prior art keywords
disease
sulfate salt
pharmaceutically acceptable
propyl
salt according
Prior art date
Application number
HRP20161612TT
Other languages
English (en)
Croatian (hr)
Inventor
Stéphane BURLET
Cécilia ESTRELLA
Mathieu BARRIER
Patricia Melnyk
Nicolas Sergeant
Luc Buee
Philippe Verwaerde
Original Assignee
Alzprotect
Inserm
Université De Lille 2 Droit Et Santé
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzprotect, Inserm, Université De Lille 2 Droit Et Santé filed Critical Alzprotect
Publication of HRP20161612T1 publication Critical patent/HRP20161612T1/hr
Publication of HRP20161612T2 publication Critical patent/HRP20161612T2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20161612TT 2012-12-27 2013-12-27 Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih HRP20161612T2 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27
EP13815780.5A EP2938597B1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (2)

Publication Number Publication Date
HRP20161612T1 HRP20161612T1 (hr) 2017-01-27
HRP20161612T2 true HRP20161612T2 (hr) 2017-02-24

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161612TT HRP20161612T2 (hr) 2012-12-27 2013-12-27 Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih

Country Status (23)

Country Link
US (3) US9562018B2 (enExample)
EP (1) EP2938597B1 (enExample)
JP (1) JP6384923B2 (enExample)
KR (1) KR102115060B1 (enExample)
CN (1) CN105008333B (enExample)
AU (2) AU2013369288B2 (enExample)
BR (1) BR112015015474B1 (enExample)
CA (1) CA2895285C (enExample)
DK (1) DK2938597T3 (enExample)
ES (1) ES2605494T3 (enExample)
HR (1) HRP20161612T2 (enExample)
HU (1) HUE030930T2 (enExample)
IL (1) IL239450B (enExample)
LT (1) LT2938597T (enExample)
MX (1) MX363367B (enExample)
NZ (1) NZ708959A (enExample)
PL (1) PL2938597T3 (enExample)
PT (1) PT2938597T (enExample)
RS (1) RS55511B1 (enExample)
RU (1) RU2655454C2 (enExample)
SI (1) SI2938597T1 (enExample)
WO (1) WO2014102339A1 (enExample)
ZA (1) ZA201504521B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55511B1 (sr) * 2012-12-27 2017-05-31 Alzprotect Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba
WO2016146655A1 (en) 2015-03-16 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
CN116249693A (zh) * 2020-10-01 2023-06-09 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的琥珀酸盐，其制备及其用途
DK4225306T3 (da) * 2020-10-07 2025-03-24 Alzprotect Anvendelse af n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-aminsulfatsalte og solvater heraf til behandling af motorneuronsygdomme og neuromuskulære forbindelseslidelser
MX2024007691A (es) 2021-12-20 2024-07-01 Alzprotect Uso de sales de succinato de n-(3-(4-(3-(diisobutilamino)propil)pi perazin-1-il)propil)-1h-benzo[d]imidazol-2-amina y solvatos del mismo para el tratamiento de enfermedades de las neuronas motoras y trastornos de la union neuromuscular.
US20250205226A1 (en) 2022-03-25 2025-06-26 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
WO1998056423A1 (fr) * 1997-06-12 1998-12-17 Transgene S.A. Nouveaux complexes lipidiques pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
HK1038749A1 (zh) 1998-09-30 2002-03-28 纽罗根公司 2-哌嗪烷基氨苯并吡咯衍生物:多巴胺受体亚型特异配体
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
EP1581517B1 (en) * 2002-12-23 2007-02-21 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
ATE524181T1 (de) * 2004-11-10 2011-09-15 Inst Nat Sante Rech Med Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
RS55511B1 (sr) * 2012-12-27 2017-05-31 Alzprotect Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba

Also Published As

Publication number Publication date
US20170151235A1 (en) 2017-06-01
US20190381036A1 (en) 2019-12-19
AU2013369288A8 (en) 2015-07-16
HUE030930T2 (hu) 2017-06-28
DK2938597T3 (en) 2017-01-09
US9562018B2 (en) 2017-02-07
ZA201504521B (en) 2016-11-30
NZ708959A (en) 2019-11-29
SI2938597T1 (sl) 2017-03-31
MX2015008502A (es) 2015-12-16
IL239450A0 (en) 2015-07-30
BR112015015474B1 (pt) 2022-04-19
AU2018202218A1 (en) 2018-04-26
RU2655454C2 (ru) 2018-05-29
BR112015015474A2 (enExample) 2017-08-15
ES2605494T3 (es) 2017-03-14
US20160108003A1 (en) 2016-04-21
US10537569B2 (en) 2020-01-21
CN105008333A (zh) 2015-10-28
HRP20161612T1 (hr) 2017-01-27
US10772884B2 (en) 2020-09-15
KR20150105313A (ko) 2015-09-16
MX363367B (es) 2019-03-20
CA2895285C (en) 2021-03-30
AU2018202218B2 (en) 2019-02-21
EP2938597B1 (en) 2016-10-26
JP6384923B2 (ja) 2018-09-05
LT2938597T (lt) 2017-01-25
RU2015130671A (ru) 2017-01-30
EP2938597A1 (en) 2015-11-04
IL239450B (en) 2018-06-28
HK1215582A1 (en) 2016-09-02
AU2013369288B2 (en) 2018-02-22
AU2013369288A1 (en) 2015-07-02
CA2895285A1 (en) 2014-07-03
PL2938597T3 (pl) 2017-03-31
CN105008333B (zh) 2018-02-09
WO2014102339A1 (en) 2014-07-03
RS55511B1 (sr) 2017-05-31
PT2938597T (pt) 2016-12-09
KR102115060B1 (ko) 2020-05-25
JP2016503813A (ja) 2016-02-08

Similar Documents

Publication Publication Date Title
HRP20161612T2 (hr) Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih
HRP20241145T1 (hr) Biciklički aza spojevi kao agonisti muskarinskih receptora
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
HRP20211331T1 (hr) Inhibitor površinskog antigena hepatitis b virusa
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
HRP20241020T1 (hr) Makrociklički spoj koji služi kao wee1 inhibitor i njegove primjene
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
HRP20211863T1 (hr) Formulacija za kontinuirano otpuštanje kolhicina i postupci priprave istog
EP2911664A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
PH12017502351A1 (en) 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
HRP20171793T1 (hr) Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata
EA200901373A1 (ru) Аминогетероциклические соединения
HRP20190857T1 (hr) Inhibitori glikozidaze
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
JP2018168191A5 (enExample)
HRP20211429T1 (hr) Derivati sobetiroma
HRP20201985T1 (hr) Piridonski spoj kao c-met inhibitor
HRP20130007T1 (hr) Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli
HRP20170025T1 (hr) Derivati tetrahidropirolotiazina kao inhibitori bace
JP2017537937A5 (enExample)
EP3861352A4 (en) NOVEL BIOMARKER FOR HUMAN ALZHEIMER'S DISEASE
JP2015526475A5 (enExample)
HRP20191869T1 (hr) Fluoroindol derivati kao pozitivni alosterički modulatori muskarinskog m1 receptora
HRP20211182T1 (hr) Dopamin d3 receptora selektivni antagonisti/djelomični agonisti; postupci izrade i njihova uporaba
NZ631388A (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation